Nault JC, Boubaya M, Wartski M, Dohan A, Pol S, Pop G, Soussan M, Sutter O, Costentin C, Roux J, Sengel C, Lequoy M, Montravers F, Menu Y, Pageaux GP, Goulart DM, Guiu B, Luciani A, Nahon P, Dioguardi Burgio M, Wagner M, Maksud P, Mulé S, Allaire M, Sidali S, Coilly A, Besson FL, …
Nahon P, Lusivika-Nzinga C, Merle P, Zoulim F, Decaens T, Ganne-Carrié N, Pageaux GP, Leroy V, Alric L, Bronowicki JP, Bourlière M, Gournay J, Tran A, Pol S, Mathurin P, Loustaud-Ratti V, Métivier S, De Ledinghen V, Abergel A, Thabut D, D’Alteroche L, Bouattour M, Asselah T, Ouzan D, Cales P, Chazouillères O, Gelu-Simeon M, …
Ganne-Carrié N, Nahon P.J Hepatol. 2024 Dec 20:S0168-8278(24)02817-4. doi: 10.1016/j.jhep.2024.12.030. Online ahead of print. Abstract Alcohol-related liver disease is the third leading cause of hepatocellular carcinoma worldwide and the leading cause in Europe. Additionally, the recent definition of metabolic dysfunction-associated steatotic liver disease with increased alcohol intake (MetALD) will enrich this population with a more …
Differences between hepatocellular carcinoma caused by alcohol and other aetiologies Read More »
Nault JC, Sritharan N, Verset G, Borbath I, Lequoy M, Allaire M, Regnault H, Colle I, Orlent H, Sinapi I, Moreno C, Larrey E, Sidali S, Hollande C, Amaddeo G, Pol S, Nahon P, Ganne-Carrié N, Levy V, Bloch-Queyrat C; Paris Liver Cancer Group; Trepo E, Bouattour M.JHEP Rep. 2024 Aug 22;6(11):101192. doi: 10.1016/j.jhepr.2024.101192. Abstract …
Vitellius C, Desjonqueres E, Lequoy M, Amaddeo G, Fouchard I, N’Kontchou G, Canivet CM, Ziol M, Regnault H, Lannes A, Oberti F, Boursier J, Ganne-Carrie N.JHEP Rep. 2024 Jun 29;6(10):101160. doi: 10.1016/j.jhepr.2024.101160. eCollection 2024 Oct.PMID: 39411648 Abstract Background & aims: Despite its growing incidence, hepatocellular carcinoma (HCC) related to metabolic dysfunction-associated steatotic liver disease (MASLD) in non-cirrhotic livers …
MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis. Read More »
Reiberger T, Lens S, Cabibbo G, Nahon P, Zignego AL, Deterding K, Elsharkawy AM, Forns X.J Hepatol. 2024 Aug;81(2):326-344. doi: 10.1016/j.jhep.2024.04.007. Epub 2024 Jun 6.PMID: 38845253 Review. Abstract Following the advent of direct-acting antivirals (DAAs), hepatitis C virus (HCV) infection can be cured in almost all infected patients. This has led to a number of clinical questions regarding …
EASL position paper on clinical follow-up after HCV cure. Read More »
Nault JC, Calderaro J, Ronot M.J Hepatol. 2024 Oct;81(4):756-762. doi: 10.1016/j.jhep.2024.05.041. Epub 2024 Jun 11.PMID: 38871125 Abstract Primary liver tumours, including benign liver tumours, hepatocellular carcinoma and cholangiocarcinoma, present a multifaceted challenge, necessitating a collaborative approach, as evidenced by the role of the multidisciplinary tumour board (MDTB). The approach to managing primary liver tumours involves specialised …
Alitti C, Rode A, Trillaud H, Merle P, Blanc JF, Blaise L, Demory A, Nkontchou G, Grando V, Ziol M, Nahon P, Ganne-Carrié N, Petit A, Seror O, Sutter O, Nault JC.Liver Int. 2024 Jun;44(6):1363-1372. doi: 10.1111/liv.15886. Epub 2024 Mar 4.PMID: 38436538 Abstract Introduction: The effectiveness of percutaneous radiofrequency ablation (RFA) in intrahepatic cholangiocarcinomas (iCCA) remains insufficiently studied. …
Boros C, Sutter O, Cauchy F, Ganne-Carrié N, Nahon P, N’kontchou G, Ziol M, Grando V, Demory A, Blaise L, Dondero F, Durand F, Soubrane O, Lesurtel M, Laurent A, Seror O, Nault JC.Liver Int. 2024 Jun;44(6):1464-1473. doi: 10.1111/liv.15900. Epub 2024 Apr 6.PMID: 38581233 Abstract Introduction: We aim to assess the long-term outcomes of percutaneous multi-bipolar radiofrequency (mbpRFA) …
Campani C, Imbeaud S, Couchy G, Ziol M, Hirsch TZ, Rebouissou S, Noblet B, Nahon P, Hormigos K, Sidali S, Seror O, Taly V, Ganne Carrie N, Laurent-Puig P, Zucman-Rossi J, Nault JC.Gut. 2024 Oct 7;73(11):1870-1882. doi: 10.1136/gutjnl-2024-331956.PMID: 39054058 Abstract Objective: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic …
